What condition primarily benefits from sapropterin therapy?

Which patients are most likely to benefit from sapropterin?

Sapropterin therapy primarily benefits people with neopterin synthase (PTPS) deficiency, the inherited metabolic condition sometimes described as hyperphenylalaninemia due to tetrahydrobiopterin (BH4) deficiency. In this disorder, sapropterin (synthetic BH4) can lower phenylalanine levels and improve dietary and metabolic control [1].

What is the key marker doctors look for?

The main target is elevated phenylalanine (commonly in newborn screening or follow-up testing for hyperphenylalaninemia). Sapropterin is used when the hyperphenylalaninemia is expected to be BH4-responsive, meaning the patient’s condition improves with BH4 supplementation [1].

Who usually does not benefit as much?

If hyperphenylalaninemia is caused by mechanisms that are not BH4-responsive (for example, classic phenylalanine hydroxylase deficiency without meaningful BH4 responsiveness), sapropterin may not reduce phenylalanine levels enough to be the main treatment. Those cases typically rely more on dietary management and other standard approaches to control phenylalanine [1].

Source

[1] https://www.drugs.com/sapropterin.html